Liposomal SN-38

{
  "id": "MLC-T-ONC-004864",
  "term": "Liposomal SN-38",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A form of the anticancer drug irinotecan that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than irinotecan alone. Liposomal SN-38 is being studied in the treatment of advanced colorectal cancer and other types of cancer. Liposomal SN-38 blocks the ability of cells to divide and grow. It may stop the growth of tumor cells. It is a type of topoisomerase inhibitor and a type of irinotecan (CPT-11) derivative. Also called SN-38 liposome.",
    "The liposomal formulation of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. SN-38 has been reported to exhibit up to 1,000-fold more cytotoxic activity against various cancer cells in vitro than irinotecan. The liposomal formulation of SN-38 increases the solubility of SN-38, which is a relatively insoluble compound, and improves the pharmacodynamic profile as compared to SN-38 alone."
  ],
  "synonyms": [
    "SN-38 liposome"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/liposomal-sn-38/"
}